We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+35.36%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$3.5M
Cap. Flow
+$129M
Cap. Flow %
34.23%
Top 10 Hldgs %
57.24%
Holding
101
New
34
Increased
16
Reduced
11
Closed
39

Top Buys

Rank Stock Value
1
AUTL
Autolus Therapeutics
AUTL
+$15.7M
2
ROIV icon
Roivant Sciences
ROIV
+$14.9M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$14.5M
4
CABA icon
Cabaletta Bio
CABA
+$11.9M
5
IMVT icon
Immunovant
IMVT
+$11.1M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$11.8M
2
ACLX
Arcellx
ACLX
+$11M
3
MRUS
Merus
MRUS
+$10.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$10.3M
5
MRK icon
Merck
MRK
+$9.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$24.8B
$37.5M 9.9%
3,553,844
+1,384,728
+64% +$14.9M
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$8.88B
$29M 7.67%
619,789
+370,214
+148% +$14.5M
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$2.02B
$26.2M 6.93%
1,100,988
+6,494
+0.6% +$145K
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.56B
$21.9M 5.78%
2,205,899
-388,637
-15% -$2.9M
IMVT icon
5
Immunovant
IMVT
$8.27B
$20.3M 5.36%
627,228
+305,213
+95% +$11.1M
AUTL
6
Autolus Therapeutics
AUTL
$383M
$18.9M 5%
2,965,721
+2,514,346
+557% +$15.7M
FOLD
7
DELISTED
Amicus Therapeutics
FOLD
$18.2M 4.82%
1,547,141
+684,326
+79% +$8.75M
CABA icon
8
Cabaletta Bio
CABA
$461M
$17.1M 4.53%
1,003,916
+553,210
+123% +$11.9M
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$13.8M 3.64%
1,161,060
+737,886
+174% +$9.84M
APLT
10
DELISTED
Applied Therapeutics
APLT
$13.7M 3.63%
2,017,016
+1,109,864
+122% +$4.98M
LLY icon
11
Eli Lilly
LLY
$1.05T
$11.7M 3.1%
15,067
– –
MRUS
12
DELISTED
Merus
MRUS
$10.5M 2.78%
233,871
-267,935
-53% -$10.9M
ACLX
13
DELISTED
Arcellx
ACLX
$9.76M 2.58%
140,267
-173,337
-55% -$11M
VTGN icon
14
VistaGen Therapeutics
VTGN
$9.4M
$9.29M 2.46%
1,848,582
+58,400
+3% +$281K
TARS icon
15
Tarsus Pharmaceuticals
TARS
$2.61B
$8.08M 2.14%
222,253
+191,263
+617% +$5.62M
PYXS icon
16
Pyxis Oncology
PYXS
$150M
$7.64M 2.02%
+1,794,195
New +$7.55M
INSM icon
17
Insmed
INSM
$23.5B
$7.39M 1.95%
272,448
+98,869
+57% +$2.77M
TRML
18
DELISTED
Tourmaline Bio
TRML
$6.28M 1.66%
+274,219
New +$9.67M
ANAB icon
19
AnaptysBio
ANAB
$1.72B
$6.07M 1.6%
269,548
+224,548
+499% +$5.32M
LRMR icon
20
Larimar Therapeutics
LRMR
$384M
$5.62M 1.49%
740,877
-42,295
-5% -$330K
IMTX icon
21
Immatics
IMTX
$1.31B
$5.17M 1.37%
491,926
-528,288
-52% -$6.16M
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
$4.96M 1.31%
+115,833
New +$5.24M
SLRN
23
DELISTED
ACELYRIN
SLRN
$4.82M 1.28%
714,773
+127,400
+22% +$968K
JANX icon
24
Janux Therapeutics
JANX
$992M
$4.58M 1.21%
+121,642
New +$2.65M
BHVN icon
25
Biohaven
BHVN
$2.32B
$4.56M 1.21%
83,461
-27,893
-25% -$1.38M
1
2 3 4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Stempoint Capital held 101 positions worth $378M, up 0.93% from $375M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Stempoint Capital deployed $129M of net new capital in Q1 2024, opening 34 new positions and adding to 16 existing holdings. Its largest new stake was Tourmaline Bio: 274,219 shares worth $6.28M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Arcellx, an estimated $11M trimmed.

  • Stempoint Capital's largest Q1 2024 buy was Tourmaline Bio: 274,219 shares worth $6.28M.
  • Stempoint Capital added most to Autolus Therapeutics in Q1 2024, an estimated $15.7M increase.
  • Stempoint Capital's biggest Q1 2024 reduction was Arcellx, cutting an estimated $11M.
  • Stempoint Capital fully exited Protagonist Therapeutics in Q1 2024, selling an estimated $11.8M.
  • Stempoint Capital's ten largest holdings make up 57% of its $378M portfolio in Q1 2024.
  • Stempoint Capital opened 34 new positions and closed 39 in Q1 2024.
  • Stempoint Capital's portfolio value rose 0.93% quarter-over-quarter to $378M.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.